Pfizer-BioNTech File for Authorization for Bivalent Booster COVID-19 Vaccine
The companies are requesting the Emergency Use Authorization (EUA) for 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.
Third Dose of COVID-19 Vaccines May Boost Immunity in Patients with Hematologic Cancers
A third dose of mRNA COVID-19 vaccines may allow most immune compromised patients with hematologic cancers to achieve antibody response levels similar to those of healthy adults after a two-dose series.
Report Finds "Mix-and-Match" COVID-19 Booster Approach More Effective
People who initially received an mRNA vaccine but were boosted with the Janssen vaccine had superior immune responses, the study found.
Novavax Seeks FDA Authorization for its COVID-19 Vaccine as Booster
If it is granted an Emergency Use Authorization (EUA), the vaccine could be used as a booster dose for individuals 18 years and older vaccinated with any of the other available COVID-19 vaccines.
Reinfection, Vaccination, and Post-Recovery Shots
Investigators sought to address the effectiveness of vaccination after COVID-19 recovery.
United Kingdom Authorizes Moderna Bivalent Booster COVID-19 Vaccine
The booster is designed for immunization against the original wild strain as well as Omicron variant.
BioNTech Says Variant COVID-19 Vaccines May Be Available as Early as October
The company and its partner, Pfizer, are preparing for the potential launch of 2 variant-adapted bivalent COVID-19 vaccines assuming authorizations from FDA and EMA.
Top 5 Infectious Disease Stories of the Week: August 5, 2022
Novavax Begins COVID-19 Vaccine Trial for Children 6 Months Through 11 Years
This study looks to identify safety, efficacy of the vaccine in the youngest pediatric populations.
Pfizer-BioNTech Begin Study Looking at Enhanced COVID-19 Vaccine
The modified spike protein in this next-generation bivalent candidate is part of the companies' strategy to try and provide vaccines with longer and more durable protection against the virus.
The Case for Variant-Specific Boosters
Omicron-specific vaccine boosters are coming, but just how necessary are they?
COVID-19 Vaccine Boosters: Benefits, Expansion of Eligibility, and Mixing and Matching of Vaccines
Clinicians offer insights on a variety of elements surrounding boosters.
A Day in the Life of a Public Health Professional
As the pandemic enters its third year, fatigue and frustration grow, but there is hope for the future.
President Biden Tests Positive for COVID-19
He is experiencing mild symptoms and is going to take Paxlovid.
CDC Director: Recommends Authorization for Novavax COVID-19 Vaccine
This decision follows votes to allow the vaccine to be indicated for prevention of the virus in adults 18 years and older.
The Best Time to Get a Booster to Prevent COVID-19 Reinfection, Breakthrough Infection
Predicted time to breakthrough infection after mRNA vaccination was significantly longer than the time to breakthrough infection after natural infection or after viral vector vaccination.
EMA Plans Anaphylaxis Label on Novavax COVID-19 Vaccine
The European agency says there have been “a few cases of anaphylaxis.” The label will also include warnings for paraesthesia and hypoaesthesia.
BA.5 Update: Caseloads, Public Health Policies, and Vaccines and Therapies
There has been an increase in transmission rates, the release of new White House strategies to address BA.5, and new potential offerings to prevent and treat the virus.
Novavax Gets Nod for FDA EUA for its COVID-19 Vaccine
The federal agency says it is indicated as a two-dose primary series for active immunization to prevent the virus in individuals 18 years of age and over.
COVID-19 in the NBA: Omicron Infection by Booster Vaccination Status
Receiving a COVID-19 booster vaccine significantly reduced Omicron infections among National Basketball Association (NBA) players and staff.
Moderna COVID-19 Booster Candidate Shows Greater Protection than Authorized Booster
The company’s investigational mRNA-1273.214 vaccine has now demonstrated significantly higher antibody titers against all tested variants.
More mRNA COVID-19 Vaccine Doses Associated with Lower Risk of Long COVID
Health care workers in Italy infected with SARS-CoV-2 were less likely to develop long COVID symptoms if they were fully vaccinated and boosted with an mRNA vaccine, a recent study found.
Top 5 Infectious Disease Stories of the Week: July 1, 2022
Here is a rundown of the most popular and significant stories we covered this past week.
Even if Previously Infected, a COVID-19 Booster Vaccine Is Essential
Antibody levels decline in individuals with hybrid immunity similarly to vaccinated individuals, meaning all people need a booster vaccine to protect against future, potentially severe, infection.
Predicting Vaccine Effectiveness Based on Genetic Distance of SARS-CoV-2 Variants
A computational framework for estimating vaccine effectiveness based on genetic differences of SARS-CoV-2 variants showed promising results in a new study that verified the model with clinical trial data.
FDA Vaccine Advisory Committee Recommends Booster Vaccines Optimized for Omicron
After an all-day meeting, the FDA’s Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted 90% YES to recommend this fall’s COVID-19 booster doses target Omicron.
The Race to Develop an Omicron-Specific Booster Vaccine
Sanofi and GSK, Pfizer-BioNTech, and Moderna are all working on booster candidates specifically designed to neutralize Omicron and its subvariants.
CDC Director Endorses ACIP Recommendation for Moderna COVID-19 Vaccine for Children and Adolescents
Rochelle P. Walensky, MD, MPH, signs off on the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) recommendation for individuals 6 through 17 years of age.
Against COVID-19, Both Natural and Vaccination-Mediated Protection Wane Over Time
Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.
Infectious Disease Vaccines: 5 Important Updates
Studies, advances, and authorizations continue in this paramount area within infectious disease.
2 Clarke Drive Cranbury, NJ 08512